The New Beauty Mandate: FDA's MoCRA Law Forces All Cosmetic Brands to Prove Product Safety

For the better part of a century, the U.S. cosmetics industry operated under a regulatory framework designed in 1938. While pharmaceutical drugs and medical devices faced rigorous pre-market approval and intense federal scrutiny, beauty brands largely functioned on an honor system. A company could formulate a new moisturizer, package it, and place it on store shelves without ever proving to the government that it was safe. That era of self-regulation has officially ended. As of 2026, the Modernization of Cosmetics Regulation Act (MoCRA) is fully operational, fundamentally rewiring the relationship between beauty brands, the federal government, and the consumer.[1][5]

Passed in late 2022 with a multi-year rollout, MoCRA represents the most significant expansion of the Food and Drug Administration's authority over cosmetics in 84 years. The law targets the structural blind spots that previously allowed contaminated or irritating products to linger on the market. By transitioning from a reactive posture to a proactive, data-rich enforcement model, the FDA is forcing every manufacturer, packer, and distributor to step out of the shadows and substantiate their safety claims with hard science.[1]

The sheer scale of this regulatory awakening is visible in the FDA's newly populated databases. Prior to MoCRA, facility registration was entirely voluntary, leaving the agency guessing about where many products were actually made. Today, the FDA's system tracks 14,299 unique, active cosmetic manufacturing facilities and nearly one million specific product listings. This mandatory registration gives regulators unprecedented visibility into the global supply chain, ensuring that both domestic and foreign manufacturers are accounted for before their goods ever reach an American consumer.

At the heart of the new mandate is a mechanism known as "safety substantiation." Under Section 608 of the act, the "responsible person"—the company whose name appears on the label—must maintain detailed records proving that their product is safe for its intended use. The burden of proof has completely shifted. Brands can no longer rely on the absence of complaints to justify a product's safety; they must proactively compile toxicological testing, ingredient safety data sheets, and peer-reviewed research to establish a "reasonable certainty" that the formula will not harm users.[1][4]

This substantiation requirement is reshaping how products are developed. Chemists and formulators are now required to conduct cumulative exposure assessments, acknowledging that the average consumer uses six to twelve different cosmetic products daily. If a specific active ingredient appears in a consumer's face wash, serum, and sunscreen, the brand must account for that compounded systemic exposure. While animal testing is not mandated, companies are heavily investing in in-vitro cell culture testing, computer modeling, and rigorous microbiological challenge tests to build their safety dossiers.[1][4][5]

If a product does cause harm, the timeline for accountability has been drastically compressed. MoCRA introduced a strict 15-business-day window for brands to report any "serious adverse events" to the FDA. This includes severe allergic reactions, infections, or any health issue requiring medical intervention. To enforce this, the FDA launched a public dashboard that makes these adverse event reports searchable by product name. This real-time transparency allows consumers, competitors, and regulators to spot dangerous trends immediately, turning safety surveillance into a public function.[1][2]

When a severe issue is identified, the FDA no longer has to ask politely for a company to pull its product. Historically, cosmetic recalls were entirely voluntary, meaning a brand could theoretically refuse to remove a contaminated item from shelves. MoCRA grants the FDA mandatory recall authority. If the agency determines there is a reasonable probability that a cosmetic will cause serious adverse health consequences, and the brand refuses to act, the FDA can force the recall and even suspend the facility's registration, effectively halting their operations.[1][3]

The regulatory landscape will continue to tighten throughout 2026. The FDA is currently drafting highly anticipated rules on fragrance allergens. For decades, brands have been allowed to hide dozens of potentially irritating chemicals under the generic umbrella term "fragrance" to protect trade secrets. The forthcoming rule, expected to be proposed in May 2026, will force companies to individually disclose specific allergens on their labels, likely triggering a massive wave of product reformulations and packaging updates across the industry.[2]

Simultaneously, the industry is bracing for the finalization of Good Manufacturing Practice (GMP) regulations. These rules will establish strict federal standards for how cosmetics are processed, packed, and held, mirroring the rigorous protocols already in place for food and pharmaceuticals. The FDA has already begun issuing warning letters to facilities that manufacture both drugs and cosmetics, signaling that strict compliance with these baseline hygiene and quality control standards will be heavily enforced.[2]

While the compliance costs for independent and legacy brands are substantial, the ultimate beneficiary of this structural shift is the consumer. By eliminating the regulatory gray areas and inflated marketing promises that have long plagued the beauty aisle, MoCRA is elevating the baseline quality of personal care. Shoppers can now trust that the products they apply to their skin, hair, and bodies are backed by scientific rigor, tracked by federal oversight, and held to a standard of safety that matches their daily importance.[5]